Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 7/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 3/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28393769 | 1.00 | POLB (0.44) | POLBL3MBTL1DPP4DPP8DPP9 | |
| SCHEMBL15207774 | 1.00 | POLB (0.44) | POLBL3MBTL1DPP4DPP8DPP9 | |
| SCHEMBL15798117 | 0.95 | POLB (0.39) | POLBL3MBTL1RAB9A | |
| SCHEMBL15798207 | 0.95 | POLB (0.39) | POLBL3MBTL1RAB9A | |
| SCHEMBL28389900 | 0.89 | POLB (0.31) | POLBL3MBTL1 | |
| SCHEMBL16612214 | 0.89 | POLB (0.31) | POLBL3MBTL1 | |
| SCHEMBL13740550 | 0.83 | POLB (0.46) | POLBL3MBTL1DPP4CHRNB2CHRNA5 | |
| SCHEMBL15608178 | 0.83 | POLB (0.46) | POLBL3MBTL1DPP4CHRNB2CHRNA5 | |
| SCHEMBL3182268 | 0.81 | POLB (0.44) | POLBL3MBTL1DPP4DPP8CHRNB2 | |
| SCHEMBL3178302 | 0.81 | POLB (0.44) | POLBL3MBTL1DPP4DPP8CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-09-14 | — | — | US | disclosed |
| CN-111153903-A | Crystal of diazabicyclooctane derivative, preparation method and application thereof, and pharmaceutical composition | 明治制果药业株式会社 | 2020-05-15 | — | — | CN | disclosed |
| US-20200048253-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-02-13 | — | — | US | disclosed |
| US-10556905-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-02-11 | — | — | US | disclosed |
| EP-2857401-B1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | MEIJI SEIKA PHARMA CO LTD (JP) | 2019-09-18 | — | — | EP | disclosed |
| US-20180258089-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-09-13 | — | — | US | disclosed |
| US-10023573-B2 | Beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-07-17 | — | — | US | disclosed |
| US-20170233393-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2017-08-17 | — | — | US | disclosed |
| US-9708320-B2 | β-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20160024090-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-9181250-B2 | Beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857401-A1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | Meiji Seika Pharma Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | POLB 3116/4885L3MBTL1 4674/4885DPP4 2978/4885 |
| US-20200048253-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | POLB 3116/4885L3MBTL1 4674/4885DPP4 2978/4885 |
| US-20160024090-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, MRPL21, FNTB | POLB 758/4885L3MBTL1 1820/4885DPP4 2753/4885 |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, FN1, FNTB | POLB 1115/4885L3MBTL1 2363/4885DPP4 2898/4885 |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | POLB 3116/4885L3MBTL1 4674/4885DPP4 2978/4885 |
| US-20180258089-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | POLB 3116/4885L3MBTL1 4674/4885DPP4 2978/4885 |
| US-10023573-B2 | Beta-lactamase inhibitor and process for preparing the same | FN1, FNTB, CPN1 | POLB 1918/4885L3MBTL1 2021/4885DPP4 1785/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | POLB 3116/4885L3MBTL1 4674/4885DPP4 2978/4885 |
| US-10556905-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | POLB 3116/4885L3MBTL1 4674/4885DPP4 2978/4885 |
| US-20170233393-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | FN1, FNTB, CPN1 | POLB 1918/4885L3MBTL1 2021/4885DPP4 1785/4885 |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | POLB 3116/4885L3MBTL1 4674/4885DPP4 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.